WAM
VRXAW

Wolverine Asset Management’s Veraxa Biotech AG Warrants VRXAW Stock Holding History

Wolverine Asset Management’s Portfolio VRXAW Stock Details VRXAW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$322 Buy
+2,917
New +$515 ﹤0.01% 1617

Other funds holding VRXAW

AIMCA
Alberta Investment Management Corp (AIMCo) Edmonton, Alberta, Canada $17.9B AUM 27.57% 1-Year Est. Return
CS
Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
WC
Wealthspring Capital West Harrison, New York $448M AUM 8.34% 1-Year Est. Return
CCM
Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $351M AUM 21.8% 1-Year Est. Return
LIM
Longfellow Investment Management Boston, Massachusetts $489M AUM 9.58% 1-Year Est. Return

Wolverine Asset Management's VRXAW Position: Q2 2026 in Review

Wolverine Asset Management opened a new position in Veraxa Biotech AG Warrants (VRXAW) in Q2 2026: 2,917 shares worth $322. The stake represents ﹤0.01% of the portfolio and ranks #1617 among its holdings.

9 funds tracked by Wall St. Rank hold VRXAW as of Q2 2026.

  • Wolverine Asset Management held 2,917 shares of Veraxa Biotech AG Warrants worth $322 as of Q2 2026.
  • Veraxa Biotech AG Warrants was a new Wolverine Asset Management position in Q2 2026.
  • Veraxa Biotech AG Warrants made up ﹤0.01% of Wolverine Asset Management's portfolio in Q2 2026, its #1617 holding.
  • 9 funds tracked by Wall St. Rank held Veraxa Biotech AG Warrants as of Q2 2026.

Based on Wolverine Asset Management's 13F filing for Q2 2026, filed 10 Aug 2026.